Hello, and welcome to the HealthEquity fourth quarter 2024 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad, and to withdraw from the question queue, please press star, then two. As a reminder, this conference is being recorded. I would now like to hand the call to Richard Putnam. Please go ahead. Thank you, MJ. Hello, everyone. Happy vernal equinox, and welcome to HealthEquity's fourth quarter fiscal year-end and 2024 earnings call, conference call. My name is Richard Putnam, Investor Relations for HealthEquity, and joining me today is Jon Kessler, President and CEO, Jim, James Lucania, Executive Vice President and CFO, and Dr. Steve Neeleman, Vice Chair and Founder of the company. Before I turn the call over to Jon, I have a couple of reminders. First, a press release announcing the financial results for our full year and fourth quarter of fiscal 2024 was issued after the market closed this afternoon. These financial results include the contributions from our wholly owned subsidiaries and accounts they administer, but do not include any impact from BenefitWallet HSA portfolio acquisition. The press release includes definitions of certain non-GAAP financial measures that we will reference today. A copy of today's press release, including reconciliations of these non-GAAP measures with comparable GAAP measures and a recording of this webcast, can be found on our investor relations website, which is ir.healthequity.com. Second, our comments and responses to your questions today reflect management's view as of today, March 19, 2024, and will contain forward-looking statements as defined by the SEC, including predictions, expectations, estimates, or other information that might be considered forward-looking. There are many important factors relating to our business, which could affect the forward-looking statements made today. These forward-looking statements are subject to risks and uncertainties that may cause the actual results to differ materially from statements made here today. We caution against placing undue reliance on these forward-looking statements, and we also encourage you to review the discussion of these factors and other risks that may affect our future results or the market price of our stocks, as detailed in our latest annual report on Form 10-K and any subsequent periodic reports filed with the SEC. We assume no obligation to revise or update these forward-looking statements in light of new information or future events. With that out of the way, let's turn the call over to Jon Kessler. Jon? Hi there. Thank you, Richard. Today is also a baseball's major. In addition to being the vernal equinox, is also baseball's opening day. Should be a national holiday. The good news is, you do not need the permission of Major League Baseball to reproduce or account this call. You don't need anyone's permission. You can just do it. So with that, thank you for joining us, and since we just held our Investor Day, Jim and I are going to keep prepared remarks brief, and of course, Steve is here for Q&A. In fiscal 2024, the team delivered double-digit year-over-year growth in revenue at 16% and reached the $1 billion in revenue milestone. Adjusted EBITDA grew more than twice as fast at 36%, and in sales, as we previously reported, new logo growth and network partner production drove a record Q4 and a strong year overall. Members and assets grew 9% and 14%, respectively, in fiscal 2024, and the team opened 949,000 new HSAs from sales. HealthEquity ended the fiscal year with 8.7 million HSA members in total. More than 30% of HSA cash is now in Enhanced Rates. Investing members and invested assets grew 13% and 28%, respectively. Total HSA assets reached $25.2 billion, and total accounts grew 5%, including from organic CDB net growth for the first time since the pandemic began. Now, if you weren't at our Investor Day, or if you were dazzled by the mountain views, listen up. Management aims to continue strong top-line growth and competitive outperformance while doubling non-GAAP net income per share from fiscal 2024 levels over the next three years. To do this, we have focused capital investment on our proprietary health accounts platform and the ecosystem to which it connects us, leveraging foundations in the cloud, in data science, and in API technology to deliver remarkable experiences, to deepen partnerships, and to drive member outcomes. We call those three Ds. We further leverage our platform through opportunistic HSA portfolio acquisitions, such as BenefitWallet, the transition of which we expect to complete in Q2. This three-year strategy will, we believe, not only build shareholder value, but also advance HealthEquity's mission, which is to save and improve lives by empowering healthcare consumers. It's important stuff. Now to Jim to detail other important stuff, which is our Q4 and fiscal 2024 performance and enhanced guidance for fiscal 2025. Jim? Thank you, Jon. First, I just want to thank all of you that joined us for our Investor Day last month. Hope you found it informative. I'll briefly highlight fourth quarter fiscal year GAAP and non-GAAP financial results. As always, we provide a reconciliation of GAAP measures to non-GAAP measures in today's press release. As a reminder, the results presented here reflect the reclassifications of our income statement we described in an 8-K filed on February 21, both for fiscal 2024 and the prior year for comparison. Fourth quarter revenue increased 12% year-over-year. Service revenue was $118.6 million, down 1% year-over-year, reflecting the final runoff of national emergency activity. Custodial revenue grew 35% to $105.4 million in the fourth quarter. The annualized interest rate yield on HSA cash was 268 basis points for the quarter. Interchange revenue grew 6% to $38.4 million. Gross profit as a percentage of revenue was 62% in the fourth quarter this year, up from 58% in the fourth quarter last year. Net income for the fourth quarter was $26.4 million, or $0.30 per share on a GAAP EPS basis. Our non-GAAP net income was $55 million, or $0.63 per share, versus $0.37 per share last year. Adjusted EBITDA for the quarter was $98.8 million, and adjusted EBITDA as a percentage of revenue was 38%, a 620 basis point improvement over the same quarter last year. For the full fiscal year of 2024, revenue was $999.6 million, which Jon generously rounded up to $1 billion, up 16% compared to last year. GAAP net income was $55.7 million, or $0.64 per diluted share, and non-GAAP net income was $195.5 million, or $2.25 per diluted share, up 71% and 65%, respectively, compared to last year. Adjusted EBITDA was $369.2 million, up 36% from the prior year, resulting in adjusted EBITDA as a percentage of revenue of 37% for this fiscal year. Turning to the balance sheet, as of January 31, 2024, cash on hand was $404 million, boosted by $243 million of cash flow from operations for the full fiscal year. The company had $875 million of debt outstanding, net of issuance costs. We continue to have a $1 billion undrawn line of credit available. We anticipate using both cash and drawing on the line of credit over the next few months in connection with the closings of the BenefitWallet HSA portfolio acquisition. Today's fiscal 2025 guidance reflects the carryforward of stronger-than-expected Q4 sales and efficiencies from the technology investments John mentioned, offset by slightly higher mix of investments versus cash in HSA assets. We expect revenue in a range between $1.14 billion and $1.16 billion. GAAP net income in a range of $73 million-$88 million, or 83-99 cents per share. We expect non-GAAP net income to be between $247 million-$262 million, or $2.79-$2.96 per share, based upon an estimated 89 million shares outstanding for the year. This is a big deposit towards our goal of doubling non-GAAP net income per share to our $4.50 goal by fiscal 2027. Finally, we expect adjusted EBITDA to be between $438 million-$458 million. Our guidance reflects an expectation for an average yield on HSA cash of approximately 300 basis points for fiscal 2025. As a reminder, we base custodial yield assumptions embedded in guidance on an analysis of forward-looking market indicators, such as the Secured Overnight Financing Rate and mid-duration Treasury forward curves. These are, of course, subject to change and not perfect predictors of future market conditions. As John mentioned, we ended fiscal 2024 with about 30% of HSA cash in Enhanced Rates and expect that mix shift from Basic Rates to continue as over 80% of new deposits flow into Enhanced Rates. Our guidance also includes the expected impacts of the BenefitWallet HSA portfolio acquisition, anticipated to be completed in multiple tranches by the end of Q2. Cost impacts include interest expense due to an increase in the amount of variable rate debt outstanding and drawdown of corporate cash to fund the acquisition and onboarding costs beyond normal seasonal costs to serve in Q1 and Q2. We expect full run-rate benefit in Q3 and beyond. We assume a non-GAAP income tax rate of approximately 25% and a diluted share count of 89 million, including common share equivalents. Based on our current full year guidance, we project a GAAP tax rate for fiscal 2025 at about 28%. As we've done in recent reporting periods, our full fiscal 2025 guidance includes a reconciliation of GAAP to the non-GAAP metrics provided in the earnings release, and a definition of all such items is included at the end of the earnings release. In addition, while the amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is included. With that, we know you have a number of questions, so let's go right to our operator for Q&A. ... Thank you. To ask a question, you may press star, then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, you may press star, then two. Today's first question comes from George Hill with Deutsche Bank. Please go ahead. Jon, I might be in trouble here because I think you guys called on me in the queue faster than I can type. When I look at the custodial rev in my model for the quarter, it looks like it was down a touch sequentially, while a lot of the KPIs that underpin that, I guess, again, I'm hoping I can fat finger my model here. Could you just kind of like break down what kind of like what metrics that drove the sequential decline in custodial revenue, where given the company's strong performance in all its other KPIs, I would have expected that to be up. Yeah, so let me give a partial response and then ask Jim to pile on. I believe, George, that one of the things that will be important for everyone this quarter to remember is that we have, as we outlined in an 8-K around our Investor Day and then discussed at Investor Day, we've made a few changes in how we in revenue classification within the three buckets of revenue on our income statement. I believe that what you may be looking at is a little bit of an apples to oranges as a result of that, because one of the things that we've done is, I think, appropriately so, given its growth, retreating the revenue that we generate from the service of managing invested assets as what it is, which is a service. And conversely, a benefit of doing that is that now the custodial line is more purely two things: it's its revenue generated from yield on HSA cash, and revenue generated from yield on client held funds. And so, you know, that's a big piece of what you're describing, I believe. Jim, you want to elaborate on that or on any other factors? Yeah. Yeah, no, that's precisely what it's going to be, and so you'll and for the benefit of everyone on the call, the details of the shifting components in the prior periods will be outlined in a footnote in the 10-K, which we'll hope to get on file as soon as possible in the next few days or so, hopefully. Yeah, and Jon, you got -- Jon and Jim, you guys detailed that, and I, I should have, I should have kind of remembered that as I was working my way through the model. And then I guess if I could just do a quick follow-up. The Enhanced Rates progress on the Enhanced Rates product. I, I guess would just love any, you know, comments that you have about like the, the selling season as you push forward and continue demand around that. Yeah, well, actually, Jim, you want to comment on this? Yeah, sorry, you broke up a little bit there, but the question was about progress of moving toward growing the enhanced rate mix? Yeah. Yeah. Yeah, that was it. Yeah, yeah. So yeah, I think what we've outlined, nothing's really changed in the strategy, so we're, you know, we'll get a little bit of a more of a step function bump up in that percentage because of the upcoming BenefitWallet placements. So getting a big slug of dollars that we can more than 80% place in Enhanced Rates is the expectation. And then the same, and the organic growth in the business is also being contributed almost 80, 80-plus% into Enhanced Rates. So you're going to see that number come up, and we've shared our goal is in that same three-year timeframe where we're trying to double non-GAAP net income per share, we're also trying to increase the percentage or the mix of cash, HSA cash and enhanced rates from 30% up to 60%. So will it be nice and even quarterly growth? No, but we'll that's the objective, to get from 30 to 60 in the next three years. Thanks, George. Super helpful. And I app- Thank you. The next question is from Stan Berenshteyn with Wells Fargo. Please go ahead. Hey, Stan. Hi, thanks for taking my questions. Maybe, maybe sticking with the, with the Enhanced Rates, it looks like annuities are holding up a bit better than five-year Treasury rates. Just curious, what kind of spread are you seeing over five-year Treasuries as you're locking in these Enhanced Rate products right now? Jim? Yeah, again, yeah, also at Investor Day, we outlined our sort of average expected spread is 5-year T plus 75 basis points on average. So, you know, some are a little higher, some a little lower, but these spreads don't actually change, right? When we have a partner, we sort of negotiate the formula. And, you know, so we're not shopping in the retail market each time we place these assets. Okay. Helpful. And maybe for the follow-up, at Investor Day, there was definitely some excitement over the, you know, chat-based communications that you're pushing forward with, with members. I'm just curious, what percentage of inbound member comms are text-based now, and how has that changed over the same time last year? Yeah, let me first say that I think the long-term vision is that, that chat is just one mechanism for this kind of stuff. There's- ... there's and then by long term, I don't mean some, I don't mean the Jetsons, I mean over our strategic horizon here. Although I guess now the Jetsons would be in the past, I don't know. But so I'm gonna answer your question in terms of both chat and other automated forms of handling calls. And so that number is you know still relatively low in terms of true automation, ignoring you know just IVR-type stuff. But low might be you know we're up to kind of 15%-20%. In addition, we've also, in the last couple of months here, rolled out a similar functionality for our client services center that handles inbounds from our clients as well as many of our brokers that we deal with. Which I frankly did not expect would be a big hit, but has been used rather aggressively. And that number has increased from, let's say, roughly 1,000 basis points over the last year. So 10%. And we're gonna try and drive it farther and faster, and the keys to doing that, in our view, are one, to continue to use the technology for what it's great at, which is improving the quality of the dialogue. And the main way we do that is by continuing to train the technology on actual experiences, backed with our VOC data, as well as with all of the data in our existing systems. The second way that we expand this is by, as I suggested a moment ago, expanding beyond the chat format. We actually just went live in the last couple of days here with our sort of first iteration of work on the voice side. I wish I could explain the details of it, but I can't. I do know that it's using a wonderful product from our partner, Google, and who is a customer of ours and also a great partner on this work. that it leverages our existing cloud infrastructure. So, we think this number can continue to grow, and the results, in our view, can be three things. One is obviously lower cost, but the second is not only a better experience for our members and clients, but actually a better experience for our agents who, you know, the agents that are part of this, you know, ultimately, while it obviously reduces the total number, the agents who are there can be better paid and really use their skills. And then lastly, looked at from the perspective of our partner ecosystem, I think we mentioned this on, at Investor Day, there are opportunities for both customization and personalization of messaging with items that are of interest to our partners. And, you know, that can be as simple as branding, but sometimes, but I think more importantly, you can, you know, get to areas like, you know, doing more personalization of what you're talking about than any human could ever do. And so, I feel great about the fact that we've kind of stepped out on this a little bit before there was a buzzword called AI, or truthfully, or generative AI, at least before I even knew it was generative AI. But, we're in a great spot, and we're leveraging our partners at Microsoft on the infrastructure side, and then obviously with this new bit, you know, on the application side of Google, and doing some really neat stuff. Thanks, Jon. Sure. Thanks. The next question comes from Glenn Santangelo with Jefferies. Please go ahead. Yeah, good evening. Thanks for taking my question. Yeah, listen, I just, you know, obviously a lot of good news to talk about on the custodial revenue side, but I was hoping we could maybe dig in a little bit to the service and interchange revenues. You know, with service revenues being down a little bit, you know, relative to the account growth that you had last year, I'm kind of curious if you could talk about the pricing environment in terms of what you saw this selling season. Then on the interchange side, I don't know if there's anything related to Change Healthcare and that issue that may have impacted the quarter, and I'll stop there. Thanks. Jim, why don't you hit the first part of Glenn's question? I'll hit the second part. Yeah, yep. The, yeah. So on the service side, what you're seeing is a couple things. So yeah, certainly, certainly the market competition remains the same, right? Nothing has changed there, so we, you know, we face competition on large market RFPs, and, we're gonna continue to face a little bit of pricing headwinds on a per product average revenue per user on the service line. The other piece you're seeing is the end of the national emergency, that like I mentioned in my comments. So you think of that as, you know, an FSA account that we have with a member that's open for several years because of the extension. You know, you might have a 2023, a 2022, and a 2021, and a 2020 year open. We count that as one account, but we're getting revenue for each of those years. So with all of those national emergency items coming to an end in Q4, you don't see the account go away, but the revenue per account does go away in that case. And then the last piece is just mix shift, right? HSA is a low service fee product relative to CDBs, so as we continue to grow HSAs faster than CDBs, we will see blended average revenue per total account come down. So you have sort of a multiple headwind there on price. Aside from all the pricing impacts, service revenue does grow, does grow with accounts. So acknowledge that, that's a little more challenging to forecast. But that's, you know, we think of sort of service and interchange together as our service revenue streams. They do grow with accounts. The piece we call service has that little extra, extra headwind of pricing pressure and mix shift. Yeah, and I was with regard to the question on Change, which I prefer to call Optum, for reasons that should be obvious, but nonetheless, we'll use Change here. We have not seen any on the revenue side, interchange flow side, we have not seen any impact in the first quarter thus far. We certainly took a look at, particularly the last couple of days of February when this kind of started out. And so far, I think so good on that front. In addition, I will say that since a lot of the kind of public discourse, and appropriately so here, has been about the speed with which providers are getting paid and pharmacies are getting paid, and therefore being able to give people access to medications and medical services, we have not had any disruption in the payments that we issue, and that includes the fact that we utilize Change as our partner for what we call virtual cards. So these are payments to physicians. The virtual card systems of Change were not impacted by this incident. And so, we continue to be able to pay our-- get our providers paid and get the, our members reimbursed and get our pharmacies paid, and that seems like a good thing. And maybe I'll just as long as you raise the topic, I'll say one other thing about it, which is, that, from a security perspective, while, while, Optum, United, Change have not, come forth with, much clarity with regard to the sort of underlying vulnerability, that was the source of this. We have-- there's been, you know, a lot of discussion in the, in the intelligence community about, in, in the cyber intelligence community, about what it might be. I suppose one benefit of that is that it's identified a number of what would have otherwise been zero-day vulnerabilities. And our team has been very active in as those kind of come out in that world, and we monitor those both through our own resources and third parties. As we monitor those, those items, we identify whether there are threats within our own systems, and if there are any threats within our own systems, we take action. But at the end of the day, it's you know yet another reminder of the fact that there's a reason why you know we spend more on cybersecurity than we do on marketing. It's both the right thing to do, and it's an appropriate thing to do. If you're gonna be a market leader, you're gonna have to step up to that, particularly in an industry where you have both health and financial data in your systems. Thanks, Glenn. Thanks, details. See you Thursday. The next question comes from Greg Peters with Raymond James. Please go ahead. Hey, Greg. Hey, good afternoon, everyone. I think this is a good segue. So you just were talking about cybersecurity, and it's your focus on that, and it's being important. I wanted to pivot to credit risk, not only with your depository, but also your enhanced yield partners. And the reason why is because, you know, you're seeing some continuing challenges inside some of the bank companies. And then secondly, there's this persistent concern about commercial real estate exposures. I'm just curious how you evaluate your partners, both on the depository enhanced yield, in the context of these types of external risks that we read about, it seems like almost every day. Yeah. You want me to start with that one, John? Look, yeah. Look, I mean, I think this is the purpose of our... We have a custodial cash committee within the company, and the board also provides oversight of the activities of that custodial cash committee, right? This is what we do. We try to diversify the portfolio of partners that we work with, and we do monitor the activity of each of those partners. On the bank deposit side, you know, we're not placing—like, these deposits are not treated as mass deposits of HealthEquity into the member banks. They're treated as many small deposits that are fully FDIC insured by the federal government. So they add up to, you know, $2,000 here and there, adds up to a large deposit with the bank. And then on the insurance side, I think as we've talked about, right, we are at the start of this program working with highly rated, the bluest of blue chip insurance company partners here. And you know, we are a- ... adding another criteria there of being a small percentage of their of any of our insurance partners' balance sheet, right? It's not just diversifying the dollars across our partners. We are trying to make sure that we're a very small part of the liabilities of said insurance company. But yes, it acknowledged that as we mix shift towards more insurance partner, our ability to risk manage becomes marginally heightened there as we don't have the FDIC pass-through. Okay, this is Greg- Can we get you back, Jon? Yes, I'm back. Okay, thanks. Sorry, Greg, go ahead. That's all right. Jon, did you want to add anything, or should I just plow into my follow-up question? Go ahead, sir. All right. So BenefitWallet is, the integration is underway. So again, when you're dealing with M&A, and you guys have a track record of this, there's always surprises and unforeseen challenges. Has anything popped up on your radar that you wanna call out that has been unusual so far? I know you've sort of identified, you know, the expectation of when you expect to transfer everything over, but just curious if it's meeting plans or where there's been some deviations. Yeah, I think, by and large, Greg, so far, so good. You know, as you know, and others may not, I know you do, but, one of the things we did with this transaction is that we structured it, such that, we're not acquiring any technology, systems or the like, and, you know, that has a number of benefits. First of all, it significantly reduces the possibility of surprises. But, in addition, it also, you know, reduces things like temporary, you know, cybersecurity threat environments, those kind of things. And, it's been a good model for us. For smaller transactions, you know, this will be the largest of, not only... In fact, this will be the largest HSA transfer, I believe, ever done, but certainly the largest of this type. And so, you know, so far, so good. What we will do is, once the transaction is complete, you know, as we do with other transactions, we'll give you a precise reporting of accounts, assets. Well, precise is the wrong word, but we'll give you a final tally of accounts and assets, so that, you know, you're able to understand the distinction between, you know, organic and these kinds of acquisitions. There was, you know, if you look back, we talked about kinda where these numbers might end up, but also the agreement itself contemplates the possibility of them being slightly higher or slightly lower, depending on any number of factors. And so, you'll be able to get a pretty, pretty clear view of how this thing ends up, and that'll be that. But so far, the team, you know, Brad, Mike Resky, Kelly King and the whole team at HealthEquity, as well as at BenefitWallet, the Conduent team there, have done a great job of moving this thing forward. And we're really excited about the fact that we now begin to, you know, welcome members, as we've begun to do in the last couple of weeks, as each of these tranches is getting 10-K or 8-K, I should say. Thanks, Greg. The next question comes from Sean Dodge with RBC Capital Markets. Please go ahead. Yep, thanks. Maybe just coming at the pricing service fee question in a little bit different ways. If we look at revenue per customer, on one of the last calls, Jon, you talked about customer fields, so fields being fees plus yields. As yields have increased, how much pushback or skin, I guess, have you had to give up on the fee side? Maybe kind of catalyzed more by the higher yields and not necessarily from any change in the competitive landscape. Is there been... I guess, has there been a meaningful shift there? Then over the longer run, should we think about average revenue per customer outside of cross-selling being pretty stable, where lower fees offset higher yields, or do you think there's some kind of net gain where higher yields, you don't necessarily have to give all of it back in fees or sorry, lower fees? Yeah. You know, what your question suggests, Sean, is, and it is an important observation, is that there is some, you know, I'm an economist, so I'll say it this way, there is some cross-elasticity between, between, what's happening with yields and, in particular, what's happening with the spot market, right? And, and pricing pressure. You know, that's a natural thing, and it makes a lot of sense, for, for, you know, from the perspective, particularly of larger customers. But I actually think when you look at it, I've been somewhat underwhelmed, I'll say, by the extent to which there has been that kind of competitive pricing pressure. I think the bigger issue is that, it is two issues. One is that, and as it relates to this year, and one is more generally is, that is the pace of, for lack of a better term, mix shift, as Jim put it earlier, and that mix shift being towards HSA, which in terms of total revenue per customer is awesome, right? Or total margin per customer, however you want to think about it, is awesome per account. But if I focus solely on service revenues, right? It's a little bit of a downer because HSAs tend to have the lowest monthly fees, and then, you know, there are a few other things. Now you've got the fees from investments in there. But, you know, they're gonna be lower service fees. Whereas conversely, for example, the highest service fee per account product is commuter, right? It's fantastic. And as well as, as COBRA, right? But I don't think anyone would say that COBRA is a big margin maker, right? So, and it's because you don't have a bunch of other revenue sources there. And so, I think that's really the biggest factor. And so, as you model this, I mean, there should be some correlation between the pace of relative growth of HSA versus the rest of our business in terms of accounts, right? And, the pressure that you might see on these, you know, for lack of a better term, unit services. Second point is that I think now more unique to this year, is that as we reported, we did very, very well with relative to our expectations this year, with our new logo business and, you know, particularly with our enterprise. And of course, enterprise where you get new logos is where you're gonna be most competitive, particularly when those logos are coming with existing assets. And so the fact that we did well on assets, right, is in part reflected. You know, the sort of other side of that coin is that you're gonna be more competitive on your HSA fees for that business. So, you know, that's a thing that's worth considering, in particular for this year, but, you know, it doesn't move the needle that much. I don't know. I mean, you know, expressed on a service fee per total account basis, maybe it's, you know, moves the needle 0.5%, I don't know. And then the last point I'd make is a little bit, you know, into our strategic planning horizon. So thinking about, you know, beyond fiscal 25, it is very much our goal, or a goal of ours to grow the non-custodial line. Remember, we think about service revenue as inclusive of interchange, and the reason we break out interchange from the rest of service revenue is just that it's big, it's material, right? But if you look at that line as a whole, or for that matter, exclude interchange if you want to, right? Our goal is very much to see that line grow. The way that's gonna happen is, you know, severalfold. The first is, as we talked about at the Investor Day, you know, it's gonna be about the growth of incremental services, right? As we talked about, both new and then, you know, turning that CDB growth from, you know, okay, now it's, we've got it to the place where notwithstanding the national emergency-type stuff, it's a, it's a, you know, it's a black—maybe it's a one, I don't know. It's black... At least a black zero, but it's not a crooked number. That will be helpful. But also incremental services around, you know, data analytics and the like, that we talked about at Investor Day. So over time, you know, we do want this thing to grow. We're never gonna shy away from the fact that, you know, the custodial business is a component of revenue, is and should be, a growth engine for the business, particularly as balances continue to grow. And that we're able- we've been able to, and I think we're gonna continue to be able to make it, you know, both, both more productive and less cyclical. But it's not like we're forgetting about the service revenue. We're gonna try and grow this over time. Okay. That's, that's helpful context. Thanks you. Thank you. Thanks, Sean. The next question is from Allen Lutz with Bank of America. Please go ahead. Sorry, aren't we gonna see Sean tomorrow? Are we gonna hear from Sean tomorrow? I think we are. Is that my imagination? That's your imagination. Well, we should be. We should be. I'm sorry, Sean. Good afternoon, and thanks for taking the questions. Thanks, Allen. I guess for Jon or Jim here, the technology and development spend has increased pretty dramatically over the past two years, but if you look at this past quarter, it was flat year-over-year. And at Investor Day, you talked about a lot of the investments you're making in digital CDB cards, cost transparency, cybersecurity. So I guess as we think about this fourth quarter number here, and we think about what's embedded in the fiscal 2025 guidance, do you expect the technology and development spend to be more flattish, or is that gonna kinda continue the growth trajectory it has over the past 24 months? Thanks. Jim, fire away. Yeah. Yeah, sure. I can take that. Yeah, so no, you should definitely not assume that the tech and dev spend is gonna be flat. I think what we've talked about in the past, and Jon and Jon's talked about before, before my time here, is that we were reaching the peak last fiscal year of the spending as a percentage of revenue, you know, so we're a little above 22%, kind of 22-ish% now. So we should start seeing more efficiency. But no, we're gonna continue to invest in the business. So the idea is efficiency at the margin level, not trying to flatten the raw dollars of tech and dev spend. Great. Thank you. Thanks, Allen. MJ, do we have another question? ... Maybe we lost MJ. Did that happen? Without MJ, we got nothing. Yeah, I can't bring up the questions. MJ has to do that. Something funny is going on. This call is very adventurous so far, everybody. It is. You know, someone's transcribing me saying this right now, aren't they? Yep. Or maybe not. Thank you for standing by. The next question- There you go. comes from Stephanie Davis with Barclays. Please go ahead. Maybe MJ didn't put me on because she knows how sticky you guys are of answering all my questions. I talk to you every week. You got us to Miami, my hometown. Stephanie got us to within, like, literally my hometown of, well, I guess in my case, Miami Beach, which is where we all were. So that was... We were, like, 50 blocks or something from where I was born. Can't- Amazing. You can't do better than that. Well, congrats on the quarter. Florida Man Jon Kessler, I have a question. Yes, ma'am. When I think about your recent Investor Day versus the last Investor Day you had, there was way less CDB talk. I'm looking at your CDB line, and we're actually seeing account growth again this year. I love a little bit of a look back and how that industrial logic of marrying HSAs and CDBs played out. When we think about the future, do you think we get to the same level of accounts we saw during the WageWorks transaction, or, or where does this—where does that line go? Thank you. I really appreciate that question, actually. I mean- Really? I appreciate them all, but this one, yes, I do. Because you noticed something that we, as we kind of looked at Investor Day and, you know, things like, sometimes things just happen as you go through it, and you don't quite notice them, and this is one of them. So, here's my thought. First, the core logic was not, we are going to... Like, we have, you know, leg one, and now we're gonna have leg two, you know, like, that sort of thing. It was that acquiring the CDB business at scale, gave us the opportunity to grow our HSA business in two ways. One, by playing on more fields, and two, by... That we weren't able to play on before, and two, of course, by giving us clients to cross-sell to. All evidence is that that happened. The easiest way to see that is that when you look at HSA at either gross HSA openings or net adds, whatever you wanna look at, right? When you look at our sales numbers, right, notwithstanding the fact that the HSA market is still growing by the same amount year-over-year, instead of capturing roughly 20% of that growth as we were pre-wage, right, now we're capturing... We'll see. I know that Devenir here put out there, we're gonna have our market announcement like 5 minutes before this earnings call. So, I'm guessing maybe they listened to the earnings call, and they used some of this information, and then- Mm-hmm ... like, in a couple of weeks, they have their thing. But they're wonderful people, and I shouldn't tease them that way. But you know, let's say from an account perspective, we're capturing, you know, a third of the market and maybe in the aggregate, you know, 30%. And so, like, it works. That having been said, I think what I would've and did say at the time of transaction, having, you know, at least some amount of expertise in that business, was that the CDB business itself was extraordinarily steady, and it turned out it wasn't. And it wasn't primarily as a result of... And I don't wanna be cheeky about it. I mean, it's primarily as a result of... I don't wanna duck responsibility, but it's primarily the result of the pandemic. And even at the outset of the pandemic, as you'll recall, we didn't anticipate the level of unsteadiness of that business. And so, you know, obviously there's the commuter component that people talk about, but in addition to that, there's the fact that the dependent care, which is part of the FSA piece, went, you know, kind of disappeared for a while, and it's still well below its prior levels. And then, thanks to some of the recovery legislation, right, we got this sort of brief a blip in COBRA that then went away. And then in addition to that, you've got the fact that the ACA marketplaces are subsidized, and that subsidy appears like it's going to continue. And so actual COBRA uptake relative to, you know, which is a portion of COBRA revenues, kind of came down. And so, like, that's a lot of movement that we were not anticipating having to deal with. And so as we look at it going forward, what we wanna be doing, as I said in earlier answers, we wanna be growing the CDB business. We wanna be taking market share. And since the business as a whole is, you know, I'm gonna put commuter aside, you know, whatever, let's assume it's kind of where it is, right? But, you know, broadly speaking, it's only gonna grow at the rate of workforce, which is, like, 1%. What, you know, when we wanna be growing at a crooked number, that means we're taking market share, right? And I think we're well positioned to do that. You know, we have more scale than anyone else. We're actually investing in the product because as a result of all of our investments, you know, two examples being. And these are not future examples, they are already happening. We are rolling out, we're in the midst of rolling out, we're about halfway through, our chip cards. And like people say, "Chip card, what's the big deal?" Well, let's so far, no one else has done something where we have a stacked card that is also a chip card, that will actually also be available on mobile wallet. What does that mean? It means that you can have two or three of our products on the same card, and there doesn't even have to be a card, right? Now, it's also not easy because it turns out that unlike regular chip cards, there's not as much standardization as the Mastercard and Visa people think there is out there in the retail world, and so there's some bumpiness there. But it's a great product. Second example is through the use of AI, we've got to a place where you can take, as you saw at Investor Day, take a picture of a receipt from Publix, can have whatever on there, we can tell you what it is, and we can approve it right then. And that's the biggest pain point with the largest of the CDB products, which is the FSA. So, I think it's reasonable to believe that we can get to a place where we're at single-digit growth in that product. And so that's the plan. We'll also look, you know, Stephanie, we will continue to look carefully at, you know, what do we need to own? What do we not need to own? You know, but it's always gonna be in the context, at least as far as I'm concerned, it's gonna be in the context of strengthening our core business. You know, everything we talked about at Investor Day in terms of new product, the Health Payment Account product we talked about, which is a form of smoothing deductible costs for people who don't, you know, who do, but also don't have the benefits of HSAs. It's always gonna be in service of two things. One is our core product, which is our custodial accounts, and the second is, you know, the mission of helping people, you know, helping empower consumers and, and in doing so, and saving and really saving and improving lives when you listen to what people say. So, you know, that being the case, that's, that's how we, that's kind of the framework through which we look at it, and I think that's a reasonable view of what you should be expecting from us over time. I would very much have expected to and liked to have gotten to that place quicker than we have. It's easy for me to blame the pandemic, but we have some responsibility for that, too, including myself. You know, that's helpful. That's helpful. It kind of shows it's more... It's not that you're not focusing on, it's just that's not an area of innovation as much, which is more kind of the focus for going forward. Well, what I think is, it's if you look at, for us, let me say it this way. A piece of in order to achieve the three-year target that we laid out, this is one of the things that in all likelihood, we're going to achieve. That is to say, to go back to, I think it was, I think it was Alan's question. I could be wrong, and if I am, I apologize. But, you know, regarding service revenue, you know, one of the things we're gonna have to achieve to get there is we're gonna have to grow that service revenue. We can grow service revenue by innovating new products and innovating, you know, and by growing our CDB space, and we can innovate within the CDB space and more. You know, given that, again, I don't think the hurdle is, like, super high, but I do think it's probably fair that it's also true that at the margin, these are not as profitable products, right? So, you know, is it always gonna be the first thing on our priority list? No. That's fair. Understood. Thanks, Stephanie. Can I sneak in one for Jim, or is this... I mean, that was a long answer. Sure. I'm also happy to- Sure. Go for it. All right. Let me annoy you with this one. So you've given us a ton of clarity on our custodial revenue. So if I look at the, the incremental EBITDA dollars in your guidance compared to your incremental custodial profit, there's a pretty big delta in that, even compared to prior years, which doesn't really square with this whole shifting of R&D dollars as opposed to, like, adding new, new headcount. So is there anything beyond conservatism to call out there about why there'd be maybe a lower conversion rate? So, maybe a little more clarity because I didn't give you guidance on custodial profit dollars. But you have given us clarity on the custodial AUM, how it trends. You've given us clarity on what's graduating, and you've also, your- Let me suggest something, Stephanie- Profit margin doesn't change. I think one factor that it's important to consider in this whole discussion is the other element of custodial, which is the CHF. In CHF world, right, custodial revenue from CHF is gonna decline this year, right? Well, why? Because, you know, per if, if, you know, depending on what one believes, but for the forward, you know, SOFR curves, so kind of plain old forward curve that, you know, CNBC talks about all day, you know, we're gonna have lower short rates later in the year. And, you know, that hasn't occurred yet, obviously, but that's reflected in our guide and so forth. So that's the one area in which, you know, that short cash area is the one area where you'll see sensitivity. And I think that's... I'm guessing that that is the biggest source of the variance that you're describing. Makes sense. Thank you much. Thanks, Stephanie. The next question comes from David Larsen with BTIG. Please go ahead. Hey, congratulations on the quarter. Can you talk a little bit about your care coordination software solution? I think it's really interesting how you can compare prices at different providers and hospitals for different procedures. It ties in perfectly with, like, the needs that high-deductible account members might have. I think it ties in great with what health plans are trying to accomplish. How many, like, plans is that deployed to? How many plans is that deployed to, please? And just any thoughts on, like, the uptake rate of it and the impact it can have on total cost trend? Thanks a lot. So, let me say first, and we tried to make this distinction at Investor Day. This item is still in beta, so it's - the deployment today is very limited. And I would describe it more as a feature in my mind than a product. And the reason I say this is as follows: There are people who've tried to build businesses out of this, as you well know, and for the most part, they have failed. And certainly in the public markets, they have not done well... And, the way we've approached it is the view that you can get 80% of the benefit with 20% of the stuff now that you have the benefits of ML for, you know, the business logic and generative AI, you know, for the UI to some extent. And so that's what we're really trying to do, and we're gonna try and do this across multiple applications. And we're not. I wouldn't, you know, I don't really think of it as a unique threat to the businesses that are in that space. They're gonna face that threat one way or the other, right? And so our approach is to partner. So, this, for example, I mean, this solution is, as we said at Investor Day, it's not, you know, it's us being able to access some of that logic, you know, through APIs and the like, and then also access some of the ML and AI services to kind of make it as good as we can. So I guess I'll just say, you know, one, this is something that's in beta. Two, I would look at it as principally as a source of support for competitive differentiation, you know, versus it's going to be, in the near term, its own revenue line. We will, I think, ultimately have, you know, some kind of, you know, a broad analytics and services business that we'll talk about more, and we began to talk about it in Investor Day, but it's early for that. And so I think the way I'd look at it is exactly as you said, which is, it's just good... It's good, strong feature, and it's an ability to deliver something that people want in a way that's easier for them to consume, and that's ultimately less expensive than it's been delivered in the past, which just means getting made more available. To your... the last part of your question, David, about sort of the impact on broader healthcare trends, here's my view. And again, I will say as a someone who's been part of and observed the battles about all of the massive, you know, all the ways that people have that are supposedly gonna bend trend, which for the most part haven't done squat over the years. Here's an interesting fact. When... And I'm sorry for the long answer, but we did keep the earlier comments short, the prepared ones. When you- if you look at healthcare as a percentage of U.S. GDP, in 2010, it was 17.2%, and the projection was that by now it would be 24%. It's still 17%, right? Nobody talks about that, but it's true. What happened? What changed? It's not... I mean, the Affordable Care Act did a bunch of good things, in my view, but it did not do much to bend the cost curve. That was not the objective. It enhanced access. The biggest change that's occurred over that period of time has been two things. One is the incremental involvement of consumers in healthcare, and the second is the reduction in cost of many of the everyday type pharmaceuticals and procedures that we do, in part because consumers are involved, in part because of all of the push towards generics and the like, even as obviously there are certain drugs that are expensive. So the way I look at it is, it's not that any of these tools per se bends the trend, it's that they all make the involvement of consumers more effective, and that in the whole is what has a positive effect on the trend, among other things, right? So that's the way we look at it, and when I look at our clients, who have been most effective and try the hardest to utilize tools effectively over the course of not one year or two years, but five years or 10 years, or in the case of, I think about one client that we've had now for 17 years, it's not like special, and it doesn't have a, you know, only a young population and all that kind of stuff. It's not a high-tech type situation. They've been successful at holding healthcare inflation through CPI and not just when CPI was 6%, right? Or 8.4%, whatever it was in last year. And so, you can do this, and it's not gonna be the magic that, that heals all of healthcare, but it's absolutely part of the toolbox, and our job is to... You know, we didn't create this tool, but we can sharpen it, and in doing so, we sharpen every other tool, whether that tool is, you know, wellness program, transparency type stuff, you know, telemedicine, whatever it may be, generics. We, you know, what we do sharpens every one of those tools, and that's how we help bend the trend, which ultimately makes healthcare more affordable, and, you know, by helping people understand it, makes some better uses of it. Thanks, David. Great. What? I feel like Richard's getting really mad at me now. He's getting mad. He's like, "These answers are way too long! The next question comes from Mark Marcon with Baird. Please go ahead. Got some really long questions. I'm just kidding. So, hey, just relative to, BenefitWallet, any updates that you can provide there, just in terms of the way, of, of what you expect? You know, Conduent had a call. Is there any reason why you shouldn't be able to achieve the same level of profitability or the same interest rates on the funds that they've achieved? Is there anything structurally different, or is there any portion of the BenefitWallet portfolio that isn't coming over to you? So I think I can give a short answer to this one. To the last part of your question, yes, the answer is... Well, there are two parts. One is the non-HSA component of the business, so that they have some FSAs and the like, and they are not part of this transaction. And they will continue to be managed by Conduent's broader human resources outsourcing business. And then secondly, of course, as in all transactions, you know, there will be some attrition, both in the midst of the transaction and some that might occur, you know, shortly thereafter. But you know, that we'll try to account for that, and we certainly have tried to account for it in our thinking. As to the first part of your question, I do think it's important to note, and I have to admit, I have not looked at the transcript of Conduent's call, but I know that the executive team there is very entertaining, so I'm guessing it was more fun than ours. But I would note that like many of our competitors, the way that Conduent... Or, let me say it this way, I'll genericize. Many of our competitors, the way that their strategy for deployment of funds is that they are deployed in banks, and importantly, they are deployed at short rates. So that means much more variability. And so if you look at, you know, fiscal, let's say, or I'm sorry, calendar 2023, like, that was an awesome strategy in calendar 2023, and it continues to be an awesome strategy, right? Until it isn't. It would, would've been a very, very difficult strategy in, let's say, calendar 2020. So, you know, as you know, we deploy on a ladder, and we've taken a number of steps to kind of make sure that's as smooth as possible. So, you know, that will be different. I would not—I don't know what Conduent said off the top of my head with regard to this, but you should think about us as deploying these assets in accordance with the ladder and process that Jim has described at length. Great. That's really helpful. Thanks. Thanks, Mark. The next question is from Jack Wallace with Guggenheim. Please go ahead. Hey, guys. I'll keep this quick. Jim, I think this one's gonna be directed at you. Just wanted to get a high level puts and takes, net of any of the reclassifications of what to be about a 50 basis point lift of the EBITDA guide for the year. I'm just wondering if that's mostly some of the benefits from the technology investments that Jon mentioned earlier, or if there's anything else we should be thinking about. Thank you. Jim? Yeah, no, nothing huge, right? We're trying to do is, you know, roll in the, you know, being a little bit ahead on sales, a little bit ahead on accounts, and trying to factor in, you know, the comment that I made during the discussion about, you know, when markets are good, you see a little bit of shift towards investment from cash. And just, you know, small adjustments down the cost line. So yeah, 50 basis points, I wanna call within the rounding error there, but just providing you a little more precision and with more perfect information here. Got it. Thank you. Thanks, Jack. Thank you. This concludes our question and answer session. I'd like to turn the call back over to Jon Kessler for closing remarks. Okay, 1 hour and 5 minutes, not bad. Thanks, everyone, for joining us. We will be releasing our 10-K shortly. Working hard to get that done for you, recognizing that there are some changes this year, and I'm sure it will be a real page-turner. Thanks all very much. Thank you, all. The conference has now concluded. Thank you for your participation. You may now disconnect your lines and have a nice day.